Literature DB >> 19843919

Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome.

Hideki Itoh1, Tomoko Sakaguchi, Wei-Guang Ding, Eiichi Watanabe, Ichiro Watanabe, Yukiko Nishio, Takeru Makiyama, Seiko Ohno, Masaharu Akao, Yukei Higashi, Naoko Zenda, Tomoki Kubota, Chikara Mori, Katsunori Okajima, Tetsuya Haruna, Akashi Miyamoto, Mihoko Kawamura, Katsuya Ishida, Iori Nagaoka, Yuko Oka, Yuko Nakazawa, Takenori Yao, Hikari Jo, Yoshihisa Sugimoto, Takashi Ashihara, Hideki Hayashi, Makoto Ito, Keiji Imoto, Hiroshi Matsuura, Minoru Horie.   

Abstract

BACKGROUND: Drugs with I(Kr)-blocking action cause secondary long-QT syndrome. Several cases have been associated with mutations of genes coding cardiac ion channels, but their frequency among patients affected by drug-induced long-QT syndrome (dLQTS) and the resultant molecular effects remain unknown. METHODS AND
RESULTS: Genetic testing was carried out for long-QT syndrome-related genes in 20 subjects with dLQTS and 176 subjects with congenital long-QT syndrome (cLQTS); electrophysiological characteristics of dLQTS-associated mutations were analyzed using a heterologous expression system with Chinese hamster ovary cells together with a computer simulation model. The positive mutation rate in dLQTS was similar to cLQTS (dLQTS versus cLQTS, 8 of 20 [40%] versus 91 of 176 [52%] subjects, P=0.32). The incidence of mutations was higher in patients with torsades de pointes induced by nonantiarrhythmic drugs than by antiarrhythmic drugs (antiarrhythmic versus others, 3 of 14 [21%] versus 5 of 6 [83%] subjects, P<0.05). When reconstituted in Chinese hamster ovary cells, KCNQ1 and KCNH2 mutant channels showed complex gating defects without dominant negative effects or a relatively mild decreased current density. Drug sensitivity for mutant channels was similar to that of the wild-type channel. With the Luo-Rudy simulation model of action potentials, action potential durations of most mutant channels were between those of wild-type and cLQTS.
CONCLUSIONS: dLQTS had a similar positive mutation rate compared with cLQTS, whereas the functional changes of these mutations identified in dLQTS were mild. When I(Kr)-blocking agents produce excessive QT prolongation (dLQTS), the underlying genetic background of the dLQTS subject should also be taken into consideration, as would be the case with cLQTS; dLQTS can be regarded as a latent form of long-QT syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843919     DOI: 10.1161/CIRCEP.109.862649

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  41 in total

1.  The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes.

Authors:  Elijah R Behr; Craig January; Eric Schulze-Bahr; Andrew A Grace; Stefan Kääb; Monica Fiszman; Shaniece Gathers; Shaavhrée Buckman; Ashraf Youssef; Munir Pirmohamed; Dan Roden
Journal:  Eur Heart J       Date:  2012-07-02       Impact factor: 29.983

2.  The S1103Y cardiac sodium channel variant is associated with implantable cardioverter-defibrillator events in blacks with heart failure and reduced ejection fraction.

Authors:  Albert Y Sun; Jason I Koontz; Svati H Shah; Jonathan P Piccini; Kent R Nilsson; Damian Craig; Carol Haynes; Simon G Gregory; Patrick M Hranitzky; Geoffrey S Pitt
Journal:  Circ Cardiovasc Genet       Date:  2011-04-15

Review 3.  Genetic testing for inherited cardiac disease.

Authors:  Arthur A M Wilde; Elijah R Behr
Journal:  Nat Rev Cardiol       Date:  2013-07-30       Impact factor: 32.419

4.  Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.

Authors:  David G Strauss; Jose Vicente; Lars Johannesen; Ksenia Blinova; Jay W Mason; Peter Weeke; Elijah R Behr; Dan M Roden; Ray Woosley; Gulum Kosova; Michael A Rosenberg; Christopher Newton-Cheh
Journal:  Circulation       Date:  2017-02-17       Impact factor: 29.690

Review 5.  Cardiovascular pharmacogenomics: current status and future directions.

Authors:  Dan M Roden
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

Review 6.  Drug-induced arrhythmia: pharmacogenomic prescribing?

Authors:  Elijah R Behr; Dan Roden
Journal:  Eur Heart J       Date:  2012-10-22       Impact factor: 29.983

7.  In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.

Authors:  Lucia Romero; Beatriz Trenor; Pei-Chi Yang; Javier Saiz; Colleen E Clancy
Journal:  J Mol Cell Cardiol       Date:  2014-03-11       Impact factor: 5.000

Review 8.  Applied pharmacogenomics in cardiovascular medicine.

Authors:  Peter Weeke; Dan M Roden
Journal:  Annu Rev Med       Date:  2013-10-02       Impact factor: 13.739

Review 9.  Pharmacogenetics of Potassium Channel Blockers.

Authors:  Dan M Roden
Journal:  Card Electrophysiol Clin       Date:  2016-06

10.  Congenital long QT syndrome with compound mutations in the KCNH2 gene.

Authors:  Sachiko Bando; Takeshi Soeki; Tomomi Matsuura; Toshiyuki Niki; Takayuki Ise; Koji Yamaguchi; Yoshio Taketani; Takashi Iwase; Hirotsugu Yamada; Tetsuzo Wakatsuki; Masashi Akaike; Takeshi Aiba; Wataru Shimizu; Masataka Sata
Journal:  Heart Vessels       Date:  2013-09-22       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.